focus -WSS

focus

author：knowledge 2025-09-03 14:38:20 - browse：8198

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： NIH chief: government has fallen behind pharma on clinical trials

WSS

Congressmen charge Covid hearing ‘could have been an email’

Cybersecurity threat forces Lurie Children's to take systems offline

NIH chief: government has fallen behind pharma on clinical trials

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Medical school prerequisites are outdated

Healthy food access boosts outcomes in two studies

entertainment

focus

focus

Alkermes shareholders re

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

The high cost of giving birth even with insurance

Today's health inequities arise from racist U.S. history, say experts

After affirmative action ruling, medical educators look to 'holistic review'

White House drug czar issues call for 'recovery

Hollywood unions extend contract negotiations for actors

Ohio still needs to do more to protect the right to abortion

Anesthesiologist group: stop taking Ozempic before surgery

NIH chief: government has fallen behind pharma on clinical trials

hotspot

ARCH Venture Partners is raising $3 billion for a life sciences fund

CVS, Rite Aid closures threaten to worsen pharmacy deserts

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

How state and local governments are sidelining science

The real point of Kenneth Smith’s execution by nitrogen gas

Congressmen charge Covid hearing ‘could have been an email’

knowledge

hotspot

knowledge

focus